Reports from the UK press is that Ovplex sales there have been...

Reports from the UK press is that Ovplex sales there have been disappointing.

Another headwind reported in Cancer Kick (9 Nov. 2011) re:
purchase of Correlogic by Vermillion. "Australian diagnostic firm Healthlinx is one company whose ambitions in the US ovarian cancer testing market could be complicated by the acquisition..... "The company is also interested in moving onto the US.... This effort could run into IP issues however. A valuation of Healthlinx done in June by Australian consulting firm Acuity Technology Management noted that Correlogic's OvaCheck panel includes three of the five proteins comprising the Ovplex panel. Given that Correlogic's OvaCheck patent was filed prior to
Healthlinx's OvaPlex patent, there remains a risk that not all claims (related to OvPlex) will be granted in all jurisdictions."